SPSB2: A Potential Drug Target and Biomarker (G84727)

Target Name: SPSB2

NCBI ID: G84727

SPSB2

SPSB2: A Potential Drug Target and Biomarker

Introduction

Sodium channels play a crucial role in many biological processes, including muscle contractions, nerve function, and brain activity. The sodium channel subfamily B (SPSB2) is a family of transmembrane proteins that are involved in these processes. SPSB2 has been identified as a potential drug target and biomarker due to its unique structure, subcellular localization, and involvement in various diseases.

Structure and Function

SPSB2 is a member of the Sodium Channel subfamily B, which is characterized by the presence of a unique transmembrane pore (termed anion channels) that allows it to regulate the entry of sodium ions. The pore is composed of a protein core and an external ion channel that are connected by a transmembrane segment. The SPSB2 protein has a unique hexagonal arrangement of its amino acid residues, with the ion channel opening in the center and the protein core extending outwards.

SPSB2 is involved in a wide range of physiological processes that rely on the regulation of sodium ions. In the brain, SPSB2 is involved in the regulation of neurotransmitter release, synaptic plasticity, and learning. It has also been shown to play a role in muscle physiology, where it contributes to muscle contractions and nerve function.

As a potential drug target, SPSB2 has been identified for its ability to modulate the activity of various ion channels, including those involved in neurotransmitter release and muscle contractions. This can make it an attractive target for the development of new pharmaceuticals for a variety of disorders , including epilepsy, schizophrenia, and neurodegenerative diseases.

In addition to its potential as a drug target, SPSB2 has also been identified as a biomarker for several diseases. The regulation of sodium ions is a critical aspect of many biological processes, and alterations in sodium ion levels can indicate the presence of underlying biological changes . SPSB2 has been shown to be involved in the regulation of ion channels in a variety of biological systems, including the brain and muscle. This suggests that changes in SPSB2 activity may be a sign of disease and could be used as a biomarker for several disorders.

Expression and Localization

SPSB2 is a widely expressed protein that is found in many different cell types, including neurons, muscle cells, and red blood cells. It is primarily expressed in the brain and muscle, where it is involved in the regulation of ion channels and neurotransmitter release. SPSB2 is also expressed in other tissues, including the heart, liver, and kidney.

SPSB2 has a unique subcellular localization that is consistent with its function in the regulation of ion channels. It is primarily expressed in the cell body and terminal tips, where it is involved in the regulation of ion channels and neurotransmitter release. This suggests that SPSB2 plays a critical role in the regulation of ion channels and neurotransmitter release, and that alterations in SPSB2 activity may be a sign of underlying biological changes.

Disease association

SPSB2 has been identified as a potential drug target and biomarker for several diseases. Its involvement in the regulation of ion channels and neurotransmitter release makes it a promising target for the development of new pharmaceuticals for a variety of disorders.

Epilepsy is a disorder that is characterized by the absence of normal brain activity. SPSB2 has been shown to play a role in the regulation of ion channels and neurotransmitter release in the brain, and alterations in SPSB2 activity may be a sign of underlying epileptic episodes. Therefore, SPSB2 has been identified as a potential drug target for the development of anti-epileptic medications.

Schizophrenia is a disorder that is characterized by the presence of hallucinations, delusions, and disorganized thinking. SPSB2 has

Protein Name: SplA/ryanodine Receptor Domain And SOCS Box Containing 2

Functions: Substrate recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:15601820, PubMed:21199876). Negatively regulates nitric oxide (NO) production and limits cellular toxicity in activated macrophages by mediating the ubiquitination and proteasomal degradation of NOS2 (PubMed:21199876). Acts as a bridge which links NOS2 with the ECS E3 ubiquitin ligase complex components ELOC and CUL5 (PubMed:21199876)

The "SPSB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPSB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets